Table 1.
Characteristics of participants at enrolment
| Characteristic | Treatment groups | ||
|---|---|---|---|
| Placebo n = 34 | Lithium n = 32 | p-value | |
| aAge (mean ± SD) years | 40.53 ± 8.71 | 39.03 ± 8.09 | 0.48 |
| Race | |||
| Black African | 100% | 100% | |
| bGender | |||
| Female | 28 (82%) | 30 (94%) | 0.26 |
| Males | 6 (18%) | 2 (6%) | |
| cYears of education | |||
| < 10 years | 16 (47%) | 14 (44%) | |
| ≥ 10 years | 18 (53%) | 18 (56%) | 0.81 |
| cCD4 count: median (IQR) | 498 (379 – 665) | 502 (391 – 649) | 0.8 |
| cGDS: median (IQR) | 1.12 (0.82 – 1.53) | 1.10 (0.8 – 1.5) | 0.79 |
| Antiretroviral therapy | |||
| NNRTI-based | 30(88%) | 26(81%) | 0.33 |
| PI-based | 4(12%) | 6(19%) | |
| cTime on treatment(months): median (IQR) | 40 (25 – 73) | 51 (22 – 77) | 0.64 |
SD Standard deviation, IQR Interquartile range, NNRTI Non-nucleoside reverse transcriptase inhibitors, PI Protease inhibitors
aUnpaired t-test
bFischer exact test
cMann-Whitney test